![]() |
市場調査レポート
商品コード
232800
心房細動:パイプライン製品の分析Atrial Fibrillation - Pipeline Review, H2 2020 |
心房細動:パイプライン製品の分析 |
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 134 Pages
納期: 即納可能
![]() |
心房細動とは、心拍数が不規則に(また往々にして急速に)なるという疾患で、人体内部の血流を停滞させる原因となっています。主な症状として、血圧低下や脱力感、軽い頭痛、意識混濁、胸痛などが挙げられます。疾病素質には、年齢や心臓病、高血圧、家族歴、飲酒などがあります。薬物治療・外科手術などが主な治療法となっています。
当レポートでは、世界各国での心房細動治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2020, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.
Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 8, 6, 1, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.